In this Whitepaper, we analyse the current and future changes in the pharmacovigilance field, and how technology plays a critical role.
Pharmacovigilance has undergone a significant path of growth and development in the last fifteen years. It has evolved from a simple function within regulatory compliance to an integral and proactive activity in the safety of drugs and devices for clinical use and post-marketing.
The future of pharmacovigilance could see the expansion of scope, such as the monitoring of drugs not only from a safety perspective, but also effectiveness, and the increased utilisation of digitization.
The digital support required will be considerable, in particular for the analysis and processing of the vast amount of data we are collecting in the real world.
What is the current regulatory framework?
What are the challenges and opportunities of evolution?
What are the innovative technological tools to support data collection, analysis andreporting?
What does the future hold for us?
With the expertise of Silvia Gabanti, Managing Director, Technology Business Unit of Arithmos, and Raffaele Di Marzo, PV Leadership and Advice, PV Safety Director of Arithmos, we aims to answer the questions above and illustrate current andfuture changes in the pharmacovigilance field.
Download now the Whitepaper:
About Arithmos
We are Business and Technology experts in the Life Sciences industry.
We support pharmaceutical, biotechnology, nutraceutical, medical device, universities, hospitals and non-profit organisations to achieve Operational Excellence through Digital Transformation and value-added Business Services.
Our Lines of Business: Clinical, Regulatory, Quality, Pharmacovigilance, Medical Affairs.
